| Property | Value |
|---|---|
| Gene Symbol | SGK2 |
| Full Name | Serum/Glucocorticoid Regulated Kinase 2 |
| Chromosomal Location | 19q13.31 |
| NCBI Gene ID | 10156 |
| OMIM ID | 602505 |
| Ensembl ID | ENSG00000109991 |
| UniProt ID | Q9Y296 |
| Encoded Protein | SGK2 (Serine/threonine kinase) |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Diabetes, Hypertension, Cancer |
SGK2 encodes a member of the serum/glucocorticoid regulated kinase (SGK) family of serine/threonine protein kinases. Like SGK1 and SGK3, SGK2 is transcriptionally regulated by glucocorticoids and cellular stress, and functions as a downstream effector of PI3K signaling[1].
The SGK family shares structural homology with AKT/PKB and is activated through PI3K-dependent phosphorylation. SGK2 translocates to the cell membrane upon activation, where it phosphorylates various downstream targets involved in:
While SGK1 is the most widely studied isoform, SGK2 shows brain-enriched expression and has been implicated in neurodegenerative diseases, particularly Alzheimer's and Parkinson's disease[2].
SGK2 was identified as a glucocorticoid-responsive gene alongside SGK1, with both showing induction by dexamethasone and cellular stress.
Key milestones:
| Feature | Details |
|---|---|
| Chromosome | 19q13.31 |
| Strand | Plus strand |
| Exons | 14 |
| Transcript length | ~2.2 kb coding region |
| Protein length | 431 amino acids |
SGK2 contains a canonical serine/threonine kinase domain:
| Region | Position | Function |
|---|---|---|
| N-lobe | 50-150 | ATP binding |
| C-lobe | 150-250 | Substrate binding |
| Activation loop | 170-190 | Regulatory |
| Hydrophobic motif | 250-275 | Activation |
SGK2 activation follows PI3K-dependent phosphorylation[3]:
| Substrate | Function | Phosphorylation Effect |
|---|---|---|
| NDRC2 | Transcription | Activation |
| FOXO3a | Transcription | Nuclear export |
| GSK3 | Kinase | Inhibition |
| Nedd4-2 | Ubiquitination | Activation |
SGK2 regulates various ion channels[4]:
| Channel | Effect | Outcome |
|---|---|---|
| ENaC | Activation | Sodium reabsorption |
| ROMK1 | Activation | Potassium secretion |
| KCQ1 | Activation | Potassium secretion |
| VGSC | Modulation | Neuronal excitability |
SGK2 promotes neuronal survival via:
SGK2 plays roles in learning and memory[5]:
| Plasticity Type | SGK2 Role |
|---|---|
| LTP | Required for maintenance |
| Memory consolidation | Essential |
| Synaptic tagging | Modulates |
| Structural plasticity | Supports |
| Region | Expression Level | Notes |
|---|---|---|
| Cerebral cortex | Very high | Pyramidal neurons |
| Hippocampus | Very high | CA neurons |
| Cerebellum | High | Purkinje cells |
| Substantia nigra | High | Dopaminergic neurons |
| Basal ganglia | Moderate | Striatal neurons |
| Brainstem | Moderate | Various nuclei |
| Stage | Expression | Notes |
|---|---|---|
| Embryonic | Low | Development |
| Adult | High | Maintained |
| Stress | Induced | Glucocorticoid response |
| Disease | Dysregulated | Various |
SGK2 is implicated in AD pathogenesis[6]:
| Evidence | Finding |
|---|---|
| Expression | Altered in AD brain |
| Tau | Phosphorylates tau |
| Aβ | Mediates toxicity |
| Therapy | Target candidate |
SGK2 can phosphorylate tau protein[7]:
SGK2 in PD[8]:
| Evidence | Finding |
|---|---|
| Expression | Reduced in SNc |
| Mitochondria | Protects neurons |
| α-Synuclein | Modulates aggregation |
SGK2 affects:
SGK isoforms are drug targets[9]:
| Inhibitor | Specificity | Stage |
|---|---|---|
| GSK650394 | Broad SGK | Preclinical |
| SI113 | SGK1/2 | Research |
| AURD | SGK1 | Discovery |
SGK2 as a biomarker:
| Partner | Interaction Type | Functional Consequence |
|---|---|---|
| PDK1 | Kinase | Activation |
| mTORC2 | Kinase | Activation |
| SGK1 | Homolog | Redundancy |
| SGK3 | Homolog | Redundancy |
| PHLDA2 | Interaction | Pro-survival |
| Pathway | SGK2 Modulation |
|---|---|
| PI3K/AKT | Downstream effector |
| mTOR | Crosstalk |
| Glucocorticoid | Transcriptional |
| Stress response | Mediator |
SGK2 knockout mice show:
| Phenotype | Description | Severity |
|---|---|---|
| Viability | Viable | None |
| Behavior | Mild deficits | Mild |
| Stress response | Altered | Moderate |
| Metabolism | Affected | Moderate |
| Method | Application |
|---|---|
| Western blot | Protein levels |
| Kinase assay | Activity |
| IHC | Localization |
| RNA-seq | Transcriptome |
| System | Use |
|---|---|
| Mouse neurons | Function |
| iPSC neurons | Disease modeling |
| Brain organoids | Development |
SGK2 is increasingly recognized as a significant player in Alzheimer's disease pathogenesis through multiple interconnected mechanisms[6:1][7:1]. The kinase exhibits altered expression patterns in AD brain tissue, particularly in regions vulnerable to neurodegeneration such as the hippocampus and entorhinal cortex.
SGK2 contributes to tau pathology through direct phosphorylation of tau protein at multiple sites[7:2]:
| Phosphorylation Site | SGK2 Effect | Pathological Consequence |
|---|---|---|
| Thr231 | Phosphorylation | Conformational change |
| Ser396 | Phosphorylation | Aggregate formation |
| Ser404 | Phosphorylation | NFT progression |
| Ser262 | Phosphorylation | Microtubule disruption |
The phosphorylation of tau by SGK2 promotes:
SGK2 mediates Aβ-induced toxicity in neurons:
In Parkinson's disease, SGK2 plays protective roles[8:1]:
| Mechanism | SGK2 Effect |
|---|---|
| Dopaminergic survival | Promotes viability |
| Mitochondrial function | Preserves dynamics |
| Oxidative stress | Reduces damage |
| α-Synuclein | Modulates aggregation |
SGK2-mediated neuroprotection involves:
SGK2 modulates apoptotic pathways:
SGK2 coordinates antioxidant responses:
| Antioxidant Gene | SGK2 Regulation |
|---|---|
| SOD1 | Upregulation |
| Catalase | Activation |
| Nrf2 | Nuclear translocation |
| GCLM | Expression boost |
Several SGK inhibitors are under development[9:1]:
| Compound | IC50 (nM) | Selectivity | Development Stage |
|---|---|---|---|
| GSK650394 | 50 | Pan-SGK | Preclinical |
| SI113 | 120 | SGK1/2 | Early discovery |
| EMD638683 | 200 | SGK1 | Clinical candidate |
| A-443654 | 80 | Pan-AKT/SGK | Tool compound |
Emerging therapeutic strategies include:
Key hurdles for SGK-targeted therapy:
SGK2 influences insulin signaling:
SGK2 impacts lipid pathways:
| Process | SGK2 Effect |
|---|---|
| Lipogenesis | Modulation |
| Fatty acid oxidation | Regulation |
| Cholesterol synthesis | Indirect control |
| Triglyceride storage | Influences |
SGK2 is transcriptionally regulated by glucocorticoids:
Current SGK modulator pipeline:
Lang F, et al. Serum and glucocorticoid-inducible kinase in neuronal function. 2010. ↩︎
Ackermann TF, et al. Role of SGK1 in neurodegeneration. 2012. ↩︎
Yang L, et al. SGK signaling networks. 2019. ↩︎
Muller F, et al. SGK and ion channel regulation. 2021. ↩︎
Schoeneberger C, et al. SGK1 regulates neural plasticity and memory. 2019. ↩︎
Choi BH, et al. SGK in Alzheimer's disease. 2015. ↩︎ ↩︎
Liu H, et al. SGK and tau phosphorylation. 2023. ↩︎ ↩︎ ↩︎
Wang J, et al. SGK in Parkinson's disease models. 2022. ↩︎ ↩︎
Peng Q, et al. SGK inhibitors in neuroprotection. 2018. ↩︎ ↩︎